Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome.
Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome.
复制标题
人类乳腺癌中的碳酸酐酶-9表达水平和预后：与治疗结果相关。
DOI：
10.1038/sj.bjc.6601122
复制
发表时间：
2003-07-21
影响因子：
8.8
通讯作者：
Sweep, C G J
中科院分区：
文献类型：
--
作者：
Span, P N;Bussink, J;Manders, P;Beex, L V A M;Sweep, C G J
在这里，我们开始通过实时定量RT-PCR评估253例乳腺癌组织样本中CA9的表达水平，并将其与无复发（RFS）生存期相关联。中位随访时间为75个月（2-168个月）。CA9的表达主要见于高级别、类固醇受体阴性的癌组织。在253例患者中，CA9水平与RFS无显著相关性（P=0.926，风险比(HR)=0.99, 95% CI= 0.80-1.22）。在与其他临床病理因素的多因素分析中，CA9 （P=0.018， HR=0.77, 95% CI=0.62 ~ 0.96）、辅助化疗与CA9的相互作用（P=0.009， HR=1.31, 95% CI=1.07 ~ 1.61）、辅助内分泌治疗与CA9的相互作用（P<0.001， HR=1.41, 95% CI=1.20 ~ 1.66）均对最终模型有显著影响。这些结果表明低CA9水平的患者比高CA9水平的患者从辅助治疗中获益更多。因此，测定CA9水平可以帮助选择不能从辅助治疗中获益的患者，这些患者的预后更有可能通过其他治疗方式得到改善。
Here, we set out to assess CA9 expression levels by real-time quantitative RT–PCR in breast cancer tissue samples obtained from 253 patients, and correlated those with relapse-free (RFS) survival. The median follow-up time was 75 months (range 2–168 months). CA9 expression was mainly found in high-grade, steroid receptor negative cancer tissues. CA9 levels were not significantly associated with RFS (P=0.926, hazard ratio (HR)=0.99, 95% CI=0.80–1.22) in the total cohort of 253 patients. In multivariate analysis with other clinicopathological factors, CA9 (P=0.018, HR=0.77, 95% CI=0.62–0.96), the interaction of adjuvant chemotherapy with CA9 (P=0.009, HR=1.31, 95% CI=1.07–1.61) and the interaction of adjuvant endocrine therapy with CA9 (P<0.001, HR=1.41, 95% CI=1.20–1.66) all contributed significantly to the final model. These results indicate that patients with low CA9 levels benefit more from adjuvant treatment than do patients with high levels. Thus, the determination of CA9 levels could aid in the selection of patients who will not benefit from adjuvant therapy, and whose prognosis will more likely improve with other treatment modalities.